Prodrug research: Futile or fertile?

Biochemical Pharmacology

Volumn 68, Issue 11, 2004, Pages 2097-2106

  Testa, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Absorption; Commentary; Drug metabolism; In situ activation; Pharmaceutical objectives; Pharmacodynamic objectives; Pharmacokinetic objectives; Prodrug design; Solubility; Tissue selective delivery

Indexed keywords

2,4 OXAZOLIDINEDIONE DERIVATIVE; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BAMBUTEROL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPECITABINE; CISPLATIN; CLOPIDOGREL; CODEINE; CYCLOSPORIN; DAPSONE; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; METHENAMINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDAZEPAM; OSELTAMIVIR; PRODRUG; SIALIDASE INHIBITOR; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; TERBUTALINE; TIRAPAZAMINE; UNINDEXED DRUG; XENOBIOTIC AGENT; ZANAMIVIR;

BREAST CANCER; CANCER RESEARCH; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 7444253306     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.07.005     Document Type: Article

References (42)

1. P. Ettmayer, G. Amidon, B. Clement, and B. Testa Lessons learned from marketed and investigational prodrugs J Med Chem. 47 2004 2393 2404
2. B. Testa, and J.M. Mayer Hydrolysis in Drug and Prodrug Metabolism - Chemistry, Biochemistry and Enzymology 2003 Wiley-VHCA Zurich
3. K. Beaumont, R. Webster, I. Gardner, and K. Dack Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist Curr Drug Metab. 4 2003 461 485
4. B. Testa, and W. Soine Principles of drug metabolism D.J. Abraham Burger's Medicinal Chemistry and Drug Discovery, vol. 2 6th ed. 2003 Wiley-Interscience Hoboken, NJ, USA 431 498
5. B. Testa, and J.M. Mayer Concepts in prodrug design to overcome pharmacokinetic problems B. Testa H. van de Waterbeemd G. Folkers R. Guy Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies 2001 Wiley-VHCA Zurich 85 95
6. W. Wang, J. Jiang, C.E. Ballard, and B. Wang Prodrug approaches in the improved delivery of peptide drugs Curr Pharm Design 5 1999 265 287
7. H.J. Lee, Z. You, D.H. Ko, and H.M. McLean Recent advances in prodrugs and antedrugs Curr Opin Drug Discov Dev. 1 1998 235 244
8. D.A. Bradley Prodrugs for improved CNS delivery Adv Drug Deliv Rev. 19 1996 171 202
9. B. Testa, and J. Caldwell Prodrugs revisited - The "ad hoc" approach as a complement to ligand design Med Res Rev. 16 1996 233 241
10. D.G. Waller, and C.F. George Prodrugs Br J Clin Pharmacol 28 1989 497 507
11. V.J. Stella, Charman WNA, and V.H. Naringrekar Prodrugs. Do they have advantages in clinical practice? Drugs 29 1985 455 473
12. C.G. Wermuth Designing prodrugs and bioprecursors G. Jolles K.R.H. Woolridge Drug Design: Fact or Fantasy? 1984 Academic Press London 47 72
13. N.J. Harper Drug latentiation E. Jucker Progress in Drug Research, vol. 4 1962 Birkhauser Basel, Switzerland 221 294
14. A. Albert Chemical aspects of selective toxicity Nature 182 1958 421 422
15. N. Bodor, and P. Buchwald Soft drug design: general principles and recent applications Med Res Rev. 20 2000 58 101
16. N. Bodor Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems B. Testa Advances in Drug Research, vol. 13 1984 Academic Press London 255 331
17. P. Benfield, and E.M. Sorkin Esmolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy Drugs 33 1987 392 412
18. J. Tréfouël, J. Tréfouël, F. Nitti, and D. Bovet Activite du p-aminophenylsulfamide sur les infections streptococciques Comptes Rend Seanc Soc Biol. 120 1935 756 762
19. R. Duncan Drug-polymer conjugates: potential for improved chemotherapy Anti-Canc. Drugs 3 1992 175 210
20. G.M. Dubowchik, and M.A. Walker Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs Pharmacol. Therap. 83 1999 67 123
21. 14C]-labelled benazepril HC1 in normal adult volunteers after single and repeated oral dose Xenobiotica. 21 1991 251 261
22. B. Testa, and J.M. Mayer Design of intramolecularly activated prodrugs Drug Metab Rev. 30 1998 787 807
23. G.M. Pauletti, S. Gangwar, T.J. Siahaan, J. Aube, and R.T. Borchardt Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies Adv Drug Deliv Rev. 27 1997 235 256
24. S. Gangwar, G.M. Pauletti, B. Wang, T.J. Siahaan, V.J. Stella, and R.T. Borchardt Prodrug strategies to enhance the intestinal absorption of peptides Drug Discov Today 2 1997 148 155
25. H.R. Sullivan, P. Roffey, and R.E. McMahon Biotransformation of 4′-ethynyl-2-fluorobiphenyl in the rat Drug Metab Disposit. 7 1979 76 80
26. N.L. Pochopin, W.N. Charman, and V.J. Stella Amino acid derivatives of dapsone as water-soluble prodrugs Int. J. Pharmaceut. 121 1995 157 167
27. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res. 12 1995 413 420
28. K. Beaumont, R. Webster, I. Gardner, and K. Dack Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist Curr Drug Metab. 4 2003 461 485
29. J.S. Oxford, and R. Lambkin Targeting influenza virus neuraminidase - a new strategy for antiviral therapy Drug Discov. Today 3 1998 448 456
30. W. Lew, X. Chen, and C.U. Kim Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor Curr Med Chem. 7 2000 663 672
31. 3H- bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro Biochem Pharmacol. 37 1988 3867 3876
32. L.Å. Svensson A prodrug approach to a long-acting beta2 agonist Drug News Perspect. 4 1991 544 549
33. G. Persson, O. Pahlm, and Y. Gnosspelius Oral bambuterol versus terbutaline in patients with asthma Curr Therap Res. 56 1995 457 465
34. L.A. Svensson, and A. Tunek The design and bioactivation of presystematically stable prodrugs Drug Metab Rev. 19 1988 165 194
35. Y. Tsukamoto, Y. Kato, M. Ura, I. Horii, H. Ishitsuka, and K. Kusuhara A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU Pharm. Res. 18 2001 1190 1202
36. J.J. Hwang, and J.L. Marshall Capecitabine: fulfilling the promise of oral chemotherapy Exp. Opin. Pharmacother. 3 2002 733 743
37. P. Savi, J.M. Pereillo, M.F. Uzabiaga, J. Combalbert, C. Picard, and J.P. Maffrand Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost. 84 2000 891 896
38. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastin Drug Metab. Disposit. 31 2003 53 59
39. T. Richter, T.E. Miirdter, G. Heinkele, J. Pleiss, S. Tatzel, and M. Schwab Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine J Pharmacol Exp Ther. 308 2004 189 197
40. W.A. Denny Synthetic DNA-targeted chemotherapeutic agents and related tumor-activated prodrugs DJ. Abraham Burger's Medicinal Chemistry and Drug Discovery, vol. 5 6th ed. 2003 Wiley Hoboken, NJ, USA 51 105
41. M.D. Hall, C. Martin, Ferguson DJP, R.M. Phillips, T.W. Hambley, and R. Callaghan Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models Biochem Pharmacol. 67 2004 17 30
42. R.J. Riley, and P. Workman Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells Biochem. Pharmacol. 43 1992 167 174